Vodafone and AstraZeneca in partnership to provide mobile health services for cardiovascular patients
13 March 2014
Vodafone and AstraZeneca have announced a global partnership to use Vodafone's mobile technology and systems to help cardiovascular patients and their healthcare professionals manage their care.
The technology will be used to support patients through their treatment journey, improving medication adherence and providing information to give patients confidence to manage their condition more effectively.
The project will be led by the Intelligent Pharmaceutical Group within AstraZeneca, part of Global Medicines Development, working with its local marketing teams. Services will be designed to work across geographies, with the ability to adapt to local variations in regulations and patient care.
Vodafone will provide the technology, infrastructure and expertise, as well as the ability to capture data from a variety of sources to improve overall engagement between patients and their healthcare professionals.
Healthcare professionals will be able to give patients the option to use these mHealth services as an integral part of the patient care process, to help them to manage their conditions. Patients will have access to personalised educational material and will benefit from coaching and treatment support to help manage their medication and lifestyle changes, and track their treatment progress.
Vodafone Director for Machine to Machine, Erik Brenneis, said, “Bringing together the best in connectivity with the best in treatment and education will create powerful and compelling outcomes for patients. AstraZeneca is a global leader in the mHealth field and we are delighted to work with them to develop these innovative services.”
Andy Jones VP Pharmaceutical Innovation at AstraZeneca commented, “It is really exciting to see the progress being made in this area. This work is an excellent example of collaboration between AstraZeneca and Vodafone. Together we believe we are delivering something that will bring real benefit to patients in this important therapeutic area.”